Smith & Nephew sees more sector deals, not under investor pressure (Reuters)
CEO sees continuing tax-driven inversion deals in sector
Low-cost hips and knees to address 5-10 pct of U.S. market
Q2 revenue $1.15 billion vs consensus $1.14 billion
Trading profit $255 million vs consensus $250 million (Updates and recasts with further share price gains)
Smith & Nephew (S&N), Europe's largest maker of artificial joints, expects continued deal-making in the medical technology sector but has not come under pressure from investors to sell out, its chief executive said on Friday.
Olivier ...
